Drug Profile
VCH 916
Alternative Names: VCH-916Latest Information Update: 18 Mar 2019
Price :
$50
*
At a glance
- Originator Shire
- Developer Vertex Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 31 Dec 2010 Discontinued - Phase-I/II for Hepatitis C in Canada (PO)
- 31 Dec 2010 Discontinued - Phase-I/II for Hepatitis C in Puerto Rico (PO)
- 31 Dec 2010 Discontinued - Phase-I/II for Hepatitis C in USA (PO)